Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. BILL
5. MRK
6. MRNA
7. ADI
8. LOW
9. TJX
10. SPCX

Go back to Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients
ASTRAZENECA PLC (NASDAQ: AZN) Delayed: 92.77 --0 (-0%)
Previous Close $92.77    52 Week High $35.04 
Open $92.77    52 Week Low $26.97 
Day High $92.77    P/E N/A 
Day Low $92.77    EPS $0.00 
Volume 3,653,351       

Bristol-Myers Squibb (NYSE: BMY) Delayed: 66.31 -1.3 (1.92%)
Previous Close $67.61    52 Week High $77.12 
Open $67.23    52 Week Low $49.03 
Day High $67.54    P/E 43.06 
Day Low $66.08    EPS $1.54 
Volume 5,300,998